Biomerica, Inc. Aktie News

IRVINE, Calif., 01. Sept. 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) berichtete heute über seine Finanzergebnisse für das am 31. Mai 2026 beendete Geschäftsjahr („Geschäftsjahr 2026“).

IRVINE, Calif., 27. Aug. 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” oder das “Unternehmen”), ein Entwickler und Hersteller diagnostischer Testsysteme, gab heute bekannt, dass es mit institutionellen und einzelnen Investoren endgültige Vereinbarungen für eine Privatplatzierung von 1.393.705 nicht registrierten Stammaktien des Unternehmens zu einem Preis von $1,60 pro Ak...

Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capi...

Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago

Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate

— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy  — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally — Up to Five Million Canadians May Have IBS, Representing a Significant and Underserved Market Opportunity

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026.